SCHEMBL1065279

SCHEMBL1065279

C[C@H](Cl)C(=O)Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4650548 1.00
SCHEMBL363514 1.00
SCHEMBL1066789 1.00
SCHEMBL16098247 0.96
Acetone SCHEMBL27831020 0.93 LMNA (0.43)
Thiourea SCHEMBL7105732 0.84 TSHR (0.35)
Ethylenediamine SCHEMBL4854643 0.84 GABRR1 (0.40)
SCHEMBL29281365 0.82 TSHR (0.39)
SCHEMBL10800909 0.82 TRPA1 (0.38)
SCHEMBL27818771 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100204324-A1 Optically Active N-(Alpha-Mercaptopropionyl)Glycine NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) 2010-08-12 US claimed
EP-2181984-A1 AN OPTICALLY ACTIVE N- (alpha-MERCAPTOPROPIONY) GLYCINE Nanjing Sanhome Pharmaceutical Co., Ltd. (CN) 2010-05-05 EP claimed
US-20260130893-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES INC (US) 2026-05-14 US disclosed
WO-2026089992-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2026-04-30 WO disclosed
US-20250388585-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES INC (US) 2025-12-25 US disclosed
US-20250376484-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES INC (US) 2025-12-11 US disclosed
WO-2025245003-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2025-11-27 WO disclosed
US-12448388-B2 PRMT5 inhibitors and uses thereof GILEAD SCIENCES, INC. (US) 2025-10-21 US disclosed
WO-2025202889-A1 HER2 MUTATION INHIBITORS ARRAY BIOPHARMA INC. (US) 2025-10-02 WO disclosed
US-20250154172-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES, INC. 2025-05-15 US disclosed
WO-2025096589-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2025-05-08 WO disclosed
US-4749804-A Preparation of stereoisomers of ketals SYNTEX (U.S.A.) INC. (US) 1988-06-07 US disclosed
US-4736061-A Process for preparing naproxen BLASCHIM S.P.A. (IT) 1988-04-05 US disclosed
EP-0163338-B1 PROCESS FOR PREPARING NAPROXEN Nobel Chemicals AB (SE) 1987-09-09 EP disclosed
US-4670603-A Process for the preparation of aryl alkyl ketones BLASCHIM S.P.A. (IT) 1987-06-02 US disclosed
US-4605758-A Preparation of α-arylalkanoic acids SYNTEX PHARMACEUTICALS INTERNATIONAL LTD. (BM) 1986-08-12 US disclosed
EP-0176142-A2 Process for the preparation of aryl alkyl ketones Nobel Chemicals AB (SE) 1986-04-02 EP disclosed
EP-0163338-A1 Process for preparing naproxen Nobel Chemicals AB (SE) 1985-12-04 EP disclosed
EP-0081993-A2 Optically active alpha-substituted aryl ketones, their preparation and their use in preparing alpha-arylalkanoic acids SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) 1983-06-22 EP disclosed
EP-0039025-A1 Derivatives of aryl ketones as sensitizers of photopolymerizable compounds for the visible spectral range, and photopolymerizable compositions comprising the said sensitizers E.I. DU PONT DE NEMOURS AND COMPANY (US) 1981-11-04 EP disclosed